A compound of Formula (II): or a stereoisomer thereof, or a pharmaceutically acceptable salt of said compound or said stereoisomer, wherein: each R X1 is independently selected from the group consisting of H, -(C 1-4 )alkyl, -(C 2-4 )alkenyl, and -(C 2-4 )alkynyl; R 1 is selected from the group consisting of phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl, wherein each of said phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl of R 1 is unsubstituted or substituted with from 1 to 3 R 1A groups; each R 1A (when present) is independently selected from the group consisting of halo, OH, CN, -(C 1-4 )alkyl, -(C 1-4 )haloalkyl, -(C 1-4 )alkoxy, -(C 1-4 )haloalkoxy, cyclopropyl, cyclobutyl, - NH 2 , -C(O)NH 2 , -C(O)N(CH 3 ) 2 , -S(O) 2 (C 1-4 )alkyl, CH 2 OH, CH 2 CH 2 OH, NH(CO)CH 3 , oxadiazole, triazole, and pyrazole; -L- is a divalent moiety selected from the group consisting of -(C(R L1 ) 2 ) p -, -C(O) -, -C(O)CH 2 -, and -CH 2 C(O)-, wherein p is 1 to 3, and each R L1 is independently selected from the group consisting of H, OH, -CH 3 , -CH 2 CH 3 , -CH 2 CF 3 , -CHF 2 , -CF 3 , and -CH 2 OH; and R 2 is selected from the group consisting of phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl, wherein each of said phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl of R 2 is unsubstituted or substituted with from 1 to 3 R 2A groups; each R 2A (when present) is independently selected from the group consisting of halo, OH, CN, -(C 1-4 )alkyl, -(C 1-4 )haloalkyl, -(C 1-4 )alkoxy, -(C 1-4 )haloalkoxy, cyclopropyl, cyclobutyl, - NH 2 , -C(O)NH 2 , -C(O)N(CH 3 ) 2 , -S(O) 2 (C 1-4 )alkyl, CH 2 OH, CH 2 CH 2 OH, NH(CO)CH 3 , oxadiazole, triazole, and pyrazole; each R X1 is independently selected from the group consisting of H, -(C 1-4 )alkyl, -(C 2-4 )alkenyl, and -(C 2-4 )alkynyl; R 1 is selected from the group consisting of phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl, wherein each of said phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl of R 1 is unsubstituted or substituted with from 1 to 3 R 1A groups; each R 1A (when present) is independently selected from the group consisting of halo, OH, CN, -(C 1-4 )alkyl, -(C 1-4 )haloalkyl, -(C 1-4 )alkoxy, -(C 1-4 )haloalkoxy, cyclopropyl, cyclobutyl, - NH 2 , -C(O)NH 2 , -C(O)N(CH 3 ) 2 , -S(O) 2 (C 1-4 )alkyl, CH 2 OH, CH 2 CH 2 OH, NH(CO)CH 3 , oxadiazole, triazole, and pyrazole; -L- is a divalent moiety selected from the group consisting of -(C(R L1 ) 2 ) p -, -C(O) -, -C(O)CH 2 -, and -CH 2 C(O)-, wherein p is 1 to 3, and each R L1 is independently selected from the group consisting of H, OH, -CH 3 , -CH 2 CH 3 , -CH 2 CF 3 , -CHF 2 , -CF 3 , and -CH 2 OH; and R 2 is selected from the group consisting of phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl, wherein each of said phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl of R 2 is unsubstituted or substituted with from 1 to 3 R 2A groups; each R 2A (when present) is independently selected from the group consisting of halo, OH, CN, -(C 1-4 )alkyl, -(C 1-4 )haloalkyl, -(C 1-4 )alkoxy, -(C 1-4 )haloalkoxy, cyclopropyl, cyclobutyl, - NH 2 , -C(O)NH 2 , -C(O)N(CH 3 ) 2 , -S(O) 2 (C 1-4 )alkyl, CH 2 OH, CH 2 CH 2 OH, NH(CO)CH 3 , oxadiazole, triazole, and pyrazole; <EOS>